Clinical Study
Nonatonic Obstetric Haemorrhage: Effectiveness of the Nonpneumatic Antishock Garment in Egypt
Table 4
Potential side effects of NASG treatment, by phase ().
| | Pre () | Post () | RR and 95% CI |
| | Any side effects, % (n) | 64.4% (145) | 67.8% (141) | RR = 1.05 | | 95% CI = 0.92–1.20 | | Respiratory symptoms/dyspnoea, % (n) | 7.1% (16) | 8.2% (17) | RR = 1.15 | | 95% CI = 0.60–2.22 | | Reduced urine output, % () | 9.8% (22) | 10.1% (21) | RR = 1.03 | | 95% CI = 0.59–1.82 | | Nausea, % (n) | 28.0% (63) | 19.2% (40) | RR = 0.69 | | 95% CI = 0.48–0.97 | | Vomiting, % (n) | 29.3% (66) | 19.7% (41) | RR = 0.67 | | 95% CI = 0.48–0.95 | | Abdominal pain, % (n) | 60.9% (137) | 60.6% (126) | RR = 0.99 | | 95% CI = 0.85–1.16 |
|
|
